当前位置:
X-MOL 学术
›
Curr. Opin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.
Current Opinion in Oncology ( IF 2.8 ) Pub Date : 2021-03-26 , DOI: 10.1097/cco.0000000000000738 Frédéric Peyrade 1 , Christian Borel 2 , Amaury Daste 3 , Carolie Even 4 , Esma Saada-Bouzid 1 , Joël Guigay 1
Current Opinion in Oncology ( IF 2.8 ) Pub Date : 2021-03-26 , DOI: 10.1097/cco.0000000000000738 Frédéric Peyrade 1 , Christian Borel 2 , Amaury Daste 3 , Carolie Even 4 , Esma Saada-Bouzid 1 , Joël Guigay 1
Affiliation
Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial multimodal therapy. Until early 2010, the median overall survival (OS) of metastatic patients was about 10 months.
中文翻译:
头颈部转移性鳞状细胞癌的全身治疗:管理变革建议。
在世界范围内,头颈癌占所有恶性肿瘤的 5%。三分之二的患者在初始多模式治疗后复发。直到 2010 年初,转移患者的中位总生存期 (OS) 约为 10 个月。
更新日期:2021-04-01
中文翻译:
头颈部转移性鳞状细胞癌的全身治疗:管理变革建议。
在世界范围内,头颈癌占所有恶性肿瘤的 5%。三分之二的患者在初始多模式治疗后复发。直到 2010 年初,转移患者的中位总生存期 (OS) 约为 10 个月。